IP Library Granted Patent US 8,389,245
Granted Patent B2
US 8,389,245 · App. 11/857,942 · Granted Mar 5, 2013

Detection of HPV

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,245
App. No.
11/857,942
Granted
Mar 5, 2013
Kind
B2
Abstract

The present invention provides compositions and methods for the detection and characterization of HPV sequences. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of HPV sequences. The present invention also provides compositions, methods and kits for screening sets of HPV sequences in a single reaction container.

Claims (29)

1. A method for detecting the presence or absence of a HPV target nucleic acid in a sample, wherein said HPV target nucleic acid is from one or more strains in a set of strains of HPV, comprising:

a) providing:

i) a sample suspected of containing a HPV target nucleic acid;

ii) a composition comprising a mixture of oligonucleotide probe sets, wherein:

A) each of said oligonucleotide probe sets comprises a first oligonucleotide and a second oligonucleotide that in combination form an invasive cleavage structure with target nucleic acid from at least two different strains of HPV in said set of strains of HPV wherein said mixture of oligonucleotide probe sets comprises the group of oligonucleotides consisting of SEQ ID NOS: 109-113, 115, 116, 160, 161, 163, 166, 173, 175, 177 and 180,

B) each of said oligonucleotide probe sets forms an invasive cleavage structure with target nucleic acid from fewer than all of the different strains in said set of strains of HPV, and

C) at least two of said probe sets are configured to form an invasive cleavage structure with target nucleic acid from each different strain of HPV in said set of strains of HPV; and

iii) a 5′ nuclease;

b) exposing said sample to said composition under reaction conditions in which, if an HPV target nucleic acid from one or more strains in said set of strains is present, at least two of said oligonucleotide probe sets hybridize to said HPV target nucleic acid to form invasive cleavage structures, and in which said at least two invasive cleavage structures are cleaved with said 5′ nuclease; and

c) detecting cleavage of said invasive cleavage structures, wherein detection of cleavage of said invasive cleavage structures is indicative of the presence of HPV target nucleic acid from at least one strain of said set of strains of HPV in said sample.

2. The method of claim 1 , wherein said HPV target nucleic acid is from strain 16, 16Ty2, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 58iso, 59, 66, 67, 68, 68var, 69, 70, or 82.

3. The method of claim 1 , wherein said mixture detects HPV strains 51, 56, and 66.

4. The method of claim 1 , wherein said mixture detects HPV strains 39, 68, 68var, 45, 59 and 18.

5. The method of claim 1 , wherein said mixture detects HPV strains 33, 52, 58, 31, 35 and 16.

6. The method of claim 1 , wherein said 5′ nuclease is a FEN-1.

7. The method of claim 1 , wherein said 5′ nuclease is thermostable.

8. The method of claim 1 , wherein said HPV target nucleic acid is amplified prior to said exposure step.

9. The method of claim 1 , wherein said mixture of oligonucleotide probe sets further comprises a pair of oligonucleotide primers configured to amplify a sequence contained in said HPV target nucleic acid in a polymerase chain reaction.

10. The method of claim 1 , wherein said HPV target nucleic acid is a synthetic nucleic acid.

11. The method of claim 1 , wherein said HPV target nucleic acid is genomic HPV nucleic acid.

12. The method of claim 1 , wherein two or more mixtures of oligonucleotide probes are used together to detect said HPV target nucleic acid.

13. The method of claim 1 , wherein two or more of said mixtures of oligonucleotide probes are used together to detect all high-risk HPV strains.

14. The method of claim 1 , wherein said sample is from the group consisting of cervical cells, cervical secretions, epithelial cells, respiratory secretions, urethral cells, cells of the anogenital region, urine, saliva and biopsy tissue.

15. The method of claim 1 , wherein said second oligonucleotides comprise a detectable label.

16. The method of claim 1 , wherein cleavage of said invasive cleavage structures cleaves said second oligonucleotide to produce a cleaved 5′ region of said second oligonucleotide, wherein said providing step further comprises providing an oligonucleotide FRET cassette, wherein said oligonucleotide FRET cassette comprises a set of interactive labels, wherein said oligonucleotide FRET cassette is configured to form a second invasive cleavage structure with said cleaved 5′ region of said second oligonucleotide.

17. The method of claim 16 , wherein said cleaving further comprises cleaving said second invasive cleavage structure.

18. The method of claim 16 , wherein said detecting comprises detecting and/or measuring a signal produced from one or more members of a set of interactive labels.

19. The method of claim 3 , wherein said mixture of oligonucleotide probe sets comprises the group of oligonucleotides consisting of SEQ ID NOS. 47, 51, 52, 79, and 80.

20. The method of claim 4 , wherein said mixture of oligonucleotide probe sets comprises the group of oligonucleotides consisting of SEQ ID NOS. 37, 38, 94, 95, 127, 129 and 142.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2013
From: HUDSON, ANGELA; ELAGIN, VECHESLAV; SANDER, TAMARA; OLSON-MUNOZ, MARILYN; AGARWAL, POONAM; CURTIS, MICHELLE; GARSHA, MICHELLE; OLSON, SARAH; IP, HON; TYLER, ILSE; KWIATKOWSKI, ROBERT W., JR.
To: THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 029688/0147 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
SECURITY AGREEMENT Recorded Jul 29, 2008
From: THIRD WAVE TECHNOLOGIES, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0780 →